Werewolf Therapeutics (NASDAQ:HOWL) Given Buy Rating at HC Wainwright

Werewolf Therapeutics (NASDAQ:HOWL)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research note issued to investors on Monday, Benzinga reports. They presently have a $15.00 price objective on the stock. HC Wainwright’s price target would suggest a potential upside of 147.12% from the stock’s current price.

Separately, JMP Securities assumed coverage on Werewolf Therapeutics in a research report on Wednesday, April 3rd. They issued a “mkt outperform” rating and a $12.00 price target for the company.

Werewolf Therapeutics Price Performance

Shares of Werewolf Therapeutics stock opened at $6.07 on Monday. Werewolf Therapeutics has a 52 week low of $1.57 and a 52 week high of $8.19. The company has a market cap of $263.13 million, a PE ratio of -5.57 and a beta of 0.71. The business has a 50 day moving average of $6.21 and a 200 day moving average of $4.67. The company has a quick ratio of 7.14, a current ratio of 7.14 and a debt-to-equity ratio of 0.29.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its earnings results on Thursday, March 7th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.10. The firm had revenue of $1.50 million for the quarter, compared to the consensus estimate of $2.75 million. Werewolf Therapeutics had a negative return on equity of 36.43% and a negative net margin of 256.33%. As a group, equities research analysts forecast that Werewolf Therapeutics will post -1.38 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in HOWL. Certuity LLC purchased a new stake in Werewolf Therapeutics during the fourth quarter valued at $39,000. Financial Perspectives Inc raised its holdings in Werewolf Therapeutics by 80.0% in the 4th quarter. Financial Perspectives Inc now owns 6,750 shares of the company’s stock worth $26,000 after purchasing an additional 3,000 shares during the period. Denali Advisors LLC purchased a new position in Werewolf Therapeutics during the first quarter valued at $172,000. PFM Health Sciences LP grew its holdings in Werewolf Therapeutics by 35.6% during the fourth quarter. PFM Health Sciences LP now owns 3,468,177 shares of the company’s stock valued at $13,387,000 after purchasing an additional 909,895 shares during the period. Finally, Lighthouse Investment Partners LLC purchased a new stake in Werewolf Therapeutics in the fourth quarter worth about $87,000. 64.84% of the stock is owned by hedge funds and other institutional investors.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.